Immunopharmacology and Immunotoxicology

  • John W. Hadden
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 288)


The two fields of immunopharmacology and immunotoxicology took their origins separately. Both derived from shared interests between areas of immunology and pharmacology. In the case of immunopharmacology the historical pressures which gave rise to its development lay in the need for a science of immunotherapy. In the case of immunotoxicology the pressures came from the need to extend toxicologic understandings to the recently elucidated systems of immunity. Once the fields began to congeal it was quickly recognized that the scientific processes involved represented two side of the same coin... i.e., “up regulation” and :“down regulation”. It was clear that the bases of the scientific methods of study were closely related -e.g., define the cellular targets, explore mechanisms of action, and integrate the in vivo effects to clarify the overall immunologic consequences to the organism in terms of resistance to cancer, infection, and autoimmunity.


Transfer Factor Thymic Epithelial Cell Thymic Involution Sodium Diethyldithiocarbamate Thymic Hormone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. Rosenthale and M. Mansmann, “Immunopharmacology,” S. P. Med. and Sci. Book Co., U.S.A. (1976).Google Scholar
  2. 2.
    J. W. Hadden, R. G. Coffey, and F. Spreafico, eds., “Comprehensive Immunology,” Plenum Med. Book Co., New York (1977).Google Scholar
  3. 3.
    J. W. Hadden, L. Chedid, P. Mullen, and F. Spreafico, eds., “Advances in Immunopharmacology,” Pergamon Press, Oxford (1981).Google Scholar
  4. 4.
    G. G. Gibson, R. Hubbard, and D. V. Parke, eds., “Immunotoxicology,”Academic Press, London (1983).Google Scholar
  5. 5.
    J. H. Dean, M. I. Luster, A. E. Munson, and H. Amos, eds., “Immunotoxicology and Immunopharmacology,” Raven Press, New York (1985).Google Scholar
  6. 6.
    E. P. Benditt, A. C. Upton, and B. D. Goldstein, eds., “Human Health and the Environment: Some Research Needs,” Report of the Third Task Force for Research Planning in Environmental Health Science, NIH Publication no. 86–1277 (1984).Google Scholar
  7. 7.
    J. H. Dean, L. D. Lauer, R. V. House, E. C. Ward, and M. J. Murray, Experience with Validation of Methodology for Immunotoxicity Assessment in Rodents, in: “Immunotoxicology,” A. Berlin, J. Dean, M. H. Draper, E. M. B. Smith, and F. Spreafico, eds., Martinus Nijhoff Publishers, Dordecht (1987).Google Scholar
  8. 8.
    J. W. Hadden, Immunotoxicology & Immunorestoration, in: “Immunotoxicology and Immunopharmacology,” J. Dean, Raven Press, New York (1985).Google Scholar
  9. 9.
    J. W. Hadden, Thymomimetic Drugs, in: “Immunopharmacology,” P. A. Miescher, L. Bolis, and M. Ghione, eds., Serono Symposia Publications, Raven Press, New York (1985).Google Scholar
  10. 10.
    J. W. Hadden, P. Cornaglia-Ferraris, and R. G. Coffey, Purine analogs as immunomodulators, in: “Progress in Immunology V,” Y. Yamamura and T. Tada, Academic Press, Japan (1983).Google Scholar
  11. 11.
    J. W. Hadden, S. Spector, A. Galy, J. L. Touraine, and E. M. Hadden, Thymic Hormones, Interleukins, Endotoxins and Thymomimetic Drugs in T-Lymphocyte Ontogeny, in: “Advances in Immunopharmacology 3,” Pergamon Press, Oxford (1986).Google Scholar
  12. 12.
    G. Renoux, The Mode of Action of Imuthiol (sodium diethyldithiocarbamate): A New Role for the Brain Neocortex and the Endocrine Liver in the Regulation of the T-Cell Lineage, in: “Immunomodulation: Agents and their Mechanisms,” R. L. Fenichel and M. A. Chirigos, eds., M. Dekker, Inc., New York (1984).Google Scholar
  13. 13.
    J. W. Hadden, A. Galy, H. Chen, Y. Wang, and E. M. Hadden, The Hormonal Regulation of Thymus and T Lymphocyte Development and Function, in: “Interactions among Nervous System, Neuroendocrine and Immune Systems,” J. W. Hadden, K. Masek, and G. Nistico, Pythagora Press, Rome (1989).Google Scholar
  14. 14.
    J. W. Hadden, H. Chen, Y. Wang, A. Galy, and E. M. Hadden, Strategies of Immune Reconstitution: Effects of Lymphokines on Murine T Cell Development in vitro and in vivo ,Life Sciences 44:V (1989).Google Scholar
  15. 15.
    A. Galy, E. M. Hadden, J. L. Touraine, and J. W. Hadden, Effects of Cytokines on Human Epithelial Cells in Culture: IL-1 Induces Thymic Epithelial Cell Proliferation and Change in Morphology, Cell Immunol. 124:13 (1989).PubMedCrossRefGoogle Scholar
  16. 16.
    A. Galy, C. A. Dinarello, T. S. Kupper, A. Kameda, and J. W. Hadden, Effects of Cytokines on Human Thymic Epithelial Cells in Culture II Recombinant IL-1 Stimulates Thymic Epithelial Cells to Produce IL-6 and GM-CSF, Cell Immunol. 129:161 (1990).PubMedCrossRefGoogle Scholar
  17. 17.
    J. W. Hadden, A. Galy, H. Chen, and E. M. Hadden, A Pituitary Factor Induces Thymic Epithelial Cell Proliferation in vitro ,Brain. Behavior and Immunity 3:149 (1989).CrossRefGoogle Scholar
  18. 18.
    J. W. Hadden, Transmembrane Signals in the Activation of T Lymphocytes by Mitogen Agents, Immunol. Today 9:235 (1988).PubMedCrossRefGoogle Scholar
  19. 19.
    R. G. Coffey, Intracellular Events During Lymphocyte Activation, in: “Handbook of Experimental Pharmacology,” vol. 85, M. A. Bray and J. Morley, eds., Springer-Verlag, Berlin (1988).Google Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • John W. Hadden
    • 1
  1. 1.Division of ImmunopharmacologyUniversity of South Florida College of MedicineTampaUSA

Personalised recommendations